InspireMD (NYSE:NSPR – Get Free Report) and Bioventus (NASDAQ:BVS – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Risk & Volatility
InspireMD has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Earnings and Valuation
This table compares InspireMD and Bioventus”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InspireMD | $10.84 million | 2.76 | -$19.92 million | ($0.64) | -1.01 |
| Bioventus | $568.09 million | 1.58 | $22.73 million | $0.80 | 13.32 |
Bioventus has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares InspireMD and Bioventus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InspireMD | -413.96% | -69.42% | -57.68% |
| Bioventus | 9.78% | 26.31% | 10.13% |
Analyst Recommendations
This is a summary of current recommendations and price targets for InspireMD and Bioventus, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
| Bioventus | 0 | 1 | 5 | 0 | 2.83 |
InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 598.65%. Bioventus has a consensus price target of $16.60, indicating a potential upside of 55.72%. Given InspireMD’s stronger consensus rating and higher probable upside, equities analysts clearly believe InspireMD is more favorable than Bioventus.
Institutional & Insider Ownership
44.8% of InspireMD shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 25.0% of InspireMD shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Bioventus beats InspireMD on 10 of the 14 factors compared between the two stocks.
About InspireMD
InspireMD is a medical technology company focused on developing devices for the treatment of carotid artery disease, a condition that can increase the risk of stroke. The company’s technology is designed to help protect against debris traveling to the brain during procedures to open narrowed arteries. Its lead product is the CGuard carotid stent system, which combines a metal stent with a fine mesh covering called MicroNet. The mesh is designed to help trap plaque and other material while allowing blood to flow through the artery.
About Bioventus
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
